Aqueous medicament preparations for the production of propellent gas-free aerosols

Abstract

The present invention relates to pharmaceutical preparations in the form of aqueous solutions for the production of propellant-free aerosols.

1 . An aqueous pharmaceutical preparation in the form of a solution for the production of propellant-free aerosols for inhalation comprising a pharmacologically active ingredient, characterised in that the pharmaceutical preparation contains a complexing agent.  
     
     
         2 . A pharmaceutical preparation according to    claim 1   , characterised in that the active ingredient is intended for application by inhalation, especially for the treatment of respiratory passage diseases.  
     
     
         3 . A pharmaceutical preparation according to    claim 2   , characterised in that the active ingredient is selected from the group betamimetics, anticholinergics, antiallergics and/or antihistamines.  
     
     
         4 . A pharmaceutical preparation according to claims  1 ,  2  or  3 , characterised in that the active ingredient is selected from the group 
 Fenotrol, Ipatropium bromide, Berotec, Atrovent, Berodual, Salbutamol, Combivent, Ba 679 Br, BEA 2108 Br, Oxivent.  
 
     
     
         5 . A pharmaceutical preparation according to any one of    claims 1    to    4   , characterised in that the complexing agent is nitrilotriacetic acid, citric acid, ascorbic acid or salts thereof.  
     
     
         6 . A pharmaceutical preparation according to any one of    claims 1    to    4   , characterised in that the complexing agent is EDTA or a salt thereof.  
     
     
         7 . A pharmaceutical preparation according to any one of    claims 1    to    6   , characterised in that the concentration of the complexing agent is between 10 and 100 mg/100 ml solution.  
     
     
         8 . A pharmaceutical preparation according to    claim 7    characterised in that the concentration of the complex former is between 25 and 75 mg/100 ml solution.  
     
     
         9 . A pharmaceutical preparation according to one of    claims 1    to    8   , characterised in that the adjuvant is a preservative.  
     
     
         10 . A pharmaceutical preparation according to    claim 9   , characterised in that the preservative is Benzalkonium chloride.  
     
     
         11 . A pharmaceutical preparation according to any one of the previous claims, characterised in that the pharmaceutical preparation contains up to 70% (by volume) ethanol.  
     
     
         12 . A pharmaceutical preparation according to one of the previous claims, characterised in that it contains the active ingredient in a concentration of 0.001 to 2 g/100 ml solution.  
     
     
         13 . A pharmaceutical preparation according to any one of the previous claims, characterised in that it contains pharmacologically acceptable adjuvant and flavouring substances.  
     
     
         14 . The use of aqueous pharmaceutical preparations in the production of propellant-free aerosols for inhalation, characterised in that the pharmaceutical preparations contain a complexing agent.  
     
     
         15 . The use according to    claim 14   , characterised in that the active ingredient is selected from the group Betamimetics, Anticholinergics, Antiallergics and/or antihistamines.  
     
     
         16 . The use according to    claim 14    or    15   , characterised in that the active ingredient is selected from the group Fenotrol, Ipatropium bromide, Berotec, Atrovent, Berodual, Salbutamol, Combivent, Ba 679 Br, BEA 2108 Br, Oxivent.  
     
     
         17 . The use according to any one of    claims 14    to    16   , characterised in that the complexing agent is nitriloacetic acid, citric acid, ascorbic acid or a salt thereof.  
     
     
         18 . The use according to any one of    claims 14    to    16   , characterised in that the complexing agent is EDTA or a salt thereof.  
     
     
         19 . The use according to    claim 18   , characterised in that the concentration of the complexing agent is between 25 and 75 mg.  
     
     
         20 . The use according to any one of    claims 14    to    19   , characterised in that the pharmaceutical preparation contains up to 70% (by volume) ethanol.  
     
     
         21 . The use according to any one of    claims 14    to    20   , characterised in that the pharmaceutical preparation contains active ingredient in a concentration of 0.001 to 2 g/100 ml solution.